You are here

Article Text

Article menu
Download PDFPDF
Commentary
HBV antigens quantity: duration and effect on functional cure

https://doi.org/10.1136/gutjnl-2021-326258

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors Both authors wrote the commentary.

    • Funding This work was supported by a Singapore Translational Research investigator award to AB (MOH-000019(MOH-StaR17Nov-0001).

    • Competing interests AB declares the following relationship with commercial entities developing therapeutics for HBV treatment. He acted as a consultant and served on the advisory boards of Assembly Biosciences, Gilead Sciences, Roche, Jansseen-Cilag, Vir, Molecular Therapies and HUMABS BioMed. AB is also a co-founder of LION TCR Pte. a biotech company developing T-cell receptors for treatment of virus-related cancers and chronic viral diseases.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles